[Skip to Navigation]
Comment & Response
July 28, 2020

Drug Prices, Rebates, and Discounts

Author Affiliations
  • 1Arnold Ventures, Washington, DC
JAMA. 2020;324(4):398-399. doi:10.1001/jama.2020.7989

To the Editor The analysis of prescription drug net price growth by Dr Hernandez and colleagues1 has 2 methodological issues that affect the interpretation of results. First, the authors overestimated the increase in discounts provided by drug manufacturers to non-Medicaid payers and underestimated the increase in discounts to Medicaid. Second, their methodology for estimating the mean growth in prices and discounts cannot be linked to drug spending.